Colin South

Colin South has extensive work experience in various leadership roles within the biotechnology industry. Colin is currently the CEO of ArkeaBio, a position they assumed in 2022. Prior to this, they served as the Vice President of Strategy at Zymergen, Inc. from 2020 to 2021.

From 2017 to 2020, Colin was the CEO of enEvolv and also briefly served as the Chief Commercial Officer. Before that, they held the CEO position at Proterro, Inc. from 2015 to 2016.

Colin's career began in 2009 when they became the CEO of Novogy Inc., a biofuels and biochemical producer. Novogy Inc. was eventually acquired by TOTAL in August 2014.

Colin also worked as the CTO at Lignol Energy Corporation from 2009 to 2011 and as the President of Mascoma Corporation from 2006 to 2008. Before that, they served as the GM of Health and Nutrition at Fonterra Cooperative Group from 2005 to 2006.

Earlier in their career, Colin was the CEO of Vialactia Biosciences from 2002 to 2005 and held the role of VP of Process Engineering at BioMetics from 2000 to 2002.

Colin South obtained a Bachelor of Engineering (BEng) degree in Chemical Engineering from the University of Canterbury, where they studied from 1980 to 1984. Later on, they pursued a PhD in Bioprocess Engineering at Dartmouth College from 1990 to 1995. Additionally, they earned a Master's Degree in Engineering Management from Dartmouth College, and that was between 1992 and 1994. There is no provided information about the start and end years for the degree named "BE (Chem & Process)" from the University of Canterbury.